Want to see TSE:RVX full AI Analyst Report?
RVX Stock Chart & Stats
C$0.10
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.10
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.04 - C$0.30
Previous CloseN/A
Volume1.00K
Average Volume (3M)37.18K
Market Cap
C$30.95M
Enterprise ValueC$97.50M
Total Cash (Recent Filing)C$50.03K
Total Debt (Recent Filing)C$75.06M
Price to Earnings (P/E)―
Beta0.62
Next Earnings
Aug 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding343,841,700
10 Day Avg. Volume62,041
30 Day Avg. Volume37,183
Financial Highlights & Ratios
PEG Ratio-7.26
Price to Book (P/B)-0.23
Price to Sales (P/S)0.00
P/FCF Ratio-5.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Targeted Epigenetic PipelineA focused BET/epigenetic program provides a clear scientific differentiation and platform expertise in a complex modality. That durable R&D specialization increases the likelihood of scientific partnerships, regulatory filings, and value capture in large cardiovascular and metabolic markets with chronic unmet needs.
Partnering-driven Commercial StrategyAn explicit partnering strategy reduces the need for full commercial infrastructure and large near-term capex. Over the medium term this approach can conserve cash, accelerate market access via established partners, and shift commercialization risk while retaining upside from milestone and royalty structures.
Improving Free Cash Outflow TrendA sequential improvement in free cash outflow, even if still negative, signals operational progress or better cost discipline. Over 2-6 months this trend can materially extend runway or reduce near-term financing needs, supporting continuity of clinical programs and partner discussions.
Bears Say
No RevenueZero revenue means the business is wholly pre-commercial and must rely on financing or partners for survival. This structural absence of operating income increases execution risk, exposes valuation to binary clinical outcomes, and forces recurrent capital raises or licensing deals.
Highly Stressed Balance SheetDeep negative equity and debt exceeding assets indicate severe solvency stress and limited financial flexibility. Over the medium term this elevates refinancing and covenant risk, increases likelihood of dilutive financings or restructurings, and constrains investment in R&D without partners.
Consistent Cash Burn And Funding DependencePersistent negative operating and free cash flow means the company cannot self-fund development. This structural cash burn forces regular capital raises, creates dilution risk, and can interrupt program timelines if markets sour or partner deals fail to materialize.
Resverlogix News
RVX FAQ
What was Resverlogix Corp. J’s price range in the past 12 months?
Resverlogix Corp. J lowest stock price was C$0.04 and its highest was C$0.30 in the past 12 months.
What is Resverlogix Corp. J’s market cap?
Resverlogix Corp. J’s market cap is C$30.95M.
When is Resverlogix Corp. J’s upcoming earnings report date?
Resverlogix Corp. J’s upcoming earnings report date is Aug 19, 2026 which is in 49 days.
How were Resverlogix Corp. J’s earnings last quarter?
Currently, no data Available
Is Resverlogix Corp. J overvalued?
According to Wall Street analysts Resverlogix Corp. J’s price is currently Overvalued.
Does Resverlogix Corp. J pay dividends?
Resverlogix Corp. J does not currently pay dividends.
What is Resverlogix Corp. J’s EPS estimate?
Resverlogix Corp. J’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Resverlogix Corp. J have?
Resverlogix Corp. J has 343,841,700 shares outstanding.
What happened to Resverlogix Corp. J’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Resverlogix Corp. J?
Currently, no hedge funds are holding shares in TSE:RVX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Resverlogix Corp. J
Resverlogix Corporation is a biotechnology firm currently in advanced clinical development, concentrating on developing treatments for illnesses where existing medical solutions are inadequate. The company's leading therapeutic compound is apabetalone (RVX-208), a selective small molecule designed to inhibit bromodomain and extra-terminal proteins. This compound is presently undergoing pivotal Phase III clinical trials for patients afflicted with conditions such as cardiovascular disease, diabetes, various stages of kidney disease (including end-stage renal disease), and neurodegenerative disorders. Furthermore, Resverlogix Corp. has forged an alliance with Eversana Life Science Services, LLC to support the forthcoming commercial rollout of apabetalone as a treatment for COVID-19 across the United States and Canada. The company's main office is located in Calgary, Canada.
Technical Analysis
XORTX Therapeutics Inc
―
BriaCell Therapeutics
―
Microbix Biosystms
―
Devonian Health Group
―
Thiogenesis Therapeutics Corp
―
Options Prices
Currently, No data available
---